Stevens-Johnson syndrome and toxic epidermal necrolysis
A drug induced, life threatening reaction with mucosal involvement and epidermal detachment. Mortality rises with every day of delay in stopping the culprit drug.
Updated: 2026-09-12
Written for clinicians and medical students
This section is a teaching reference for doctors, residents and medical students. It is not patient guidance and not a substitute for clinical examination, and it must not be used for self treatment.
What to do now
- Stop every non-essential drug immediately, above all the likely culprit.
- Admit. Detachment over 10 percent of body surface area needs burns or intensive care level support.
- Assess the airway, eyes, mouth and genital mucosa on day one and involve ophthalmology early.
- Calculate SCORTEN for prognosis, and start fluid, temperature, nutrition and analgesia management.
Recognition
- Prodrome of fever and malaise, then painful skin preceding any visible rash.
- Dusky macules with atypical targets, becoming confluent, with a positive Nikolsky sign.
- Mucosal erosions at two or more sites: eyes, mouth, genitals.
- Onset typically 4 to 28 days after starting the responsible drug.
Common culprit drugs
- Allopurinol, carbamazepine, lamotrigine, phenytoin, phenobarbital.
- Sulphonamide antibiotics, nevirapine, oxicam non-steroidal anti-inflammatory drugs.
- Record every drug started in the preceding 8 weeks with dates, and document the culprit in the notes and to the patient.
Differential diagnosis
- Staphylococcal scalded skin syndrome: children, no mucosal erosion, superficial split.
- Erythema multiforme major: typical targets, often herpes related, limited mucosal disease.
- Generalised bullous fixed drug eruption, acute graft versus host disease, autoimmune blistering disease.
Management principles
- Supportive care is the backbone: warm environment, fluid balance, nutrition, analgesia, non-adherent dressings, no debridement of detached skin as a routine.
- Eye care from day one prevents the commonest long term disability.
- Immunomodulation is debated. Ciclosporin and etanercept have the strongest supporting data; systemic corticosteroids and intravenous immunoglobulin remain controversial [1].
- Document the culprit drug as an allergy, and counsel the patient and first degree relatives, including HLA associations in susceptible groups.
